Live Investor Briefing

Prescient Therapeutics (ASX: PTX)

Friday, 5th April 12pm (AEDT)

Join Prescient CEO and Managing Director Steven Yatomi-Clarke for a special investor briefing on targeted cell therapy PTX-100.

Steven will discuss:

  • The new PTX-100 Phase 1b clinical study results, following their unveiling at the American Society of Hematology (ASH) conference.
  • The next steps for PTX-100 including preparation for a meeting with the FDA to discuss using the Phase 2 trial as a registrational study.
  • The potential significance of accelerating approval and commercialisation of PTX-100 in an orphan disease.

This is a live and interactive online session, and participants are encouraged to ask questionsSpots are limited, so secure yours today.

Can’t make this time, register to receive the replay.

Attend the session

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.

Featured Speaker

 Michael Davidson

Steven Yatomi-Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.

Dr Rebecca Lim

Dr Rebecca Lim

Senior Vice President of Scientific Affairs

Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.